Prof Szabo Discusses the Progresses of the Quest of Biomarkers in NASH
Discover the progresses of the quest for biomarkers in NASH with Prof Szabo
Video Prof Szabo Discusses the Progresses of the Quest of Biomarkers in NASH -Copyright ©2022 by PanNash™ Initiative - All rights reserved.
- Prof. Gyongyi Szabo
- June 24, 2019
- More Diagnosis
Would you like to read more?
Prof. Gyongyi Szabo
Gyongyi Szabo, MD, PhD is the Worcester Foundation for Biomedical Research Endowed Chair, Professor and Vice Chair of Medicine and Associate Provost at the University of Massachusetts Medical School. Dr. Szabo is an internationally recognized leader in the field of liver immunology and inflammation.
Nordic NASH Symposium
PanNASH speaker; Dr. Stephen Harrison takes part in the Nordic NASH symposium which aims to discuss management and diagnosis strategies…
The role of circadian clocks in the pathogenesis of NAFLD
The circadian clock controls rhythms responsible for regulating bodily functions, e.g., appropriate eating times. When this clock becomes disrupted due…
Hepatocellular carcinoma surveillance in NAFLD patients
Nonalcoholic fatty liver disease (NAFLD) is characterised by the presence of hepatic steatosis without significant alcohol consumption or concomitant liver…
MAFLD and inflammatory bowel disease: a prospective cohort study
MAFLD and inflammatory bowel disease: a prospective cohort study
Coffee achieves its beneficial effects through modulation of insulin resistance in a NAFLD mouse model
Coffee achieves its beneficial effects through modulation of insulin resistance in a NAFLD mouse model
B cells aggravate NASH: an innate and adaptive signalling
In this study, F. Barrow et al. (University of Minnesota Medical School, Minneapolis, USA) report that NASH livers accumulate B…
NAFLD: from drivers to targets
In this review, A. Santos-Laso et al. (Marqués de Valdecilla University Hospital, Valdecilla Biomedical Research Institute, Santander, Spain) summarise the…
NASH: an Overview Through 200 Years of Clinical Research
Although the term 'fatty liver hepatitis' first appeared in 1962, it was in 1980 that the term 'non-alcoholic steatohepatitis' (NASH)…
Immune cell-mediated features of NASH
In this review, T. Huby and E. L. Gautier (Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France) discuss “current concepts…
Steatohepatitis: hypothesis for a pathomechanism
In this article, P. M. Abuja et al. (Medical University of Graz, Austria) propose that steatohepatitis develops in four phases…
Fatty liver through the ages: Nonalcoholic steatohepatitis
In this article, Z. M. Younossi et al. (Inova Health System, Falls Church, VA, USA) aimed to review the current…
Parsing the role of PPARs in macrophage processes
In this review, D. Toobian et al. (University of California San Diego, CA, USA) underline emerging evidence of the potential…